Table 2.
RISH and marker screening results in all samples
| ID | Diagnosis | EcPV2 RISH | p53 | MCM7 | Ki67 | ||||
|---|---|---|---|---|---|---|---|---|---|
| GS | DNS | b | nb | b | nb | b | nb | ||
| 1 | SCC (G3) | pos | 2 | 3 | 2 | 4 | 3 | 1 | 1 |
| 2 | SCC (G2) | pos | 4 | 4 | 3 | 4 | 2 | 0 | 0 |
| 3 | SCC (G3) | pos | 7 | 4 | 2 | 4 | 2 | 2 | 1 |
| 4 | early SCC (G3) | pos | 0 | 4 | 2 | 4 | 2 | 0 | 0 |
| 5 | early SCC (G3) | pos | 3 | 4 | 3 | 4 | 3 | 3 | 1 |
| 6 | CIS | pos | 1 | 4 | 3 | 4 | 3 | 3 | 2 |
| 7 | CIS | (pos) | 0 | 4 | 3 | 4 | 2 | 2 | 1 |
| 8 | CIS | (pos) | 0 | 2 | 2 | 4 | 3 | 2 | 2 |
| 9 | Papilloma | pos | 27 | 4 | 1 | 4 | 3 | 1 | 1 |
| 10 | Papilloma | pos | 0 | 4 | 1 | 4 | 2 | 3 | 1 |
| 11 | Papilloma | pos | 69 | 4 | 2 | 4 | 4 | 3 | 2 |
| 12 | Papilloma | pos | 8 | 4 | 1 | 4 | 2 | 2 | 1 |
| 13 | Papilloma | pos | 14 | 4 | 1 | 4 | 3 | 2 | 1 |
| 14 | Hyperplasia | pos | 98 | 2 | 1 | 4 | 1 | 1 | 1 |
| 15 | Hyperplasia | pos | 72 | 3 | 1 | 4 | 2 | 2 | 1 |
| 16 | Hyperplasia | pos | 27 | 2 | 1 | 4 | 2 | 2 | 1 |
| 17 | Hyperplasia | pos | 84 | 2 | 1 | 4 | 2 | 3 | 1 |
| 18 | Hyperplasia | pos | 7 | 4 | 1 | 4 | 2 | 2 | 1 |
| 19 | Hyperplasia | pos | 49 | 4 | 2 | 4 | 1 | 2 | 1 |
| 9a | normal adjacent skin | neg | 0 | 2 | 1 | 4 | 1 | 1 | 0 |
| 12a | normal adjacent skin | neg | 0 | 3 | 2 | 4 | 1 | 1 | 1 |
| 14a | normal adjacent skin | neg | 0 | 2 | 1 | 4 | 2 | 2 | 1 |
| 15a | normal adjacent skin | neg | 0 | 3 | 2 | 4 | 1 | 2 | 1 |
| 16a | normal adjacent skin | neg | 0 | 2 | 1 | 4 | 1 | 2 | 1 |
Pos: positive; (pos): weak positive, neg: negative; b: basal layer; nb: non-basal layers; 0: negative; 1: < 10% of cells positive; 2: 10–50% of cells positive; 3: 51–90% of cells positive; 4: > 90% of cells positive